Abstract Number: 2279 • 2019 ACR/ARP Annual Meeting
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Background/Purpose: Women with active Rheumatoid Arthritis (RA) are more prone to relapses and complications during pregnancy. The potential risks of disease activation and treatment during…Abstract Number: 2280 • 2019 ACR/ARP Annual Meeting
Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention
Background/Purpose: Reproductive health intention screening is critical in women with systemic rheumatic diseases, as both disease activity and medication use can impact pregnancy outcomes. However,…Abstract Number: 2281 • 2019 ACR/ARP Annual Meeting
The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years
Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage…Abstract Number: 2282 • 2019 ACR/ARP Annual Meeting
Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population
Background/Purpose: Women of reproductive age with rheumatic diseases are often prescribed teratogenic medications; thus, reproductive counseling is important. A prior study demonstrated improvement in counseling…Abstract Number: 2283 • 2019 ACR/ARP Annual Meeting
Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients
Background/Purpose: While the benefits of breastfeeding for both the mother and her infant are well established, available resources regarding medication compatibility with lactation are limited. …Abstract Number: 2284 • 2019 ACR/ARP Annual Meeting
The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development
Background/Purpose: Recently, the progression of treatment strategy enabled many systemic lupus erythematosus (SLE) women to become mothers. On the other hand, some reports have revealed…Abstract Number: 2285 • 2019 ACR/ARP Annual Meeting
Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers
Background/Purpose: Prospective cohort studies of pregnancies managed by experts demonstrate that up to 30% of systemic lupus erythematosus (SLE) pregnancies result in preterm birth. We…Abstract Number: 2286 • 2019 ACR/ARP Annual Meeting
Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?
Background/Purpose: The German pregnancy register Rhekiss is designed as a nationwide, web-based longitudinal observational register established in 2015. The register follows women with inflammatory rheumatic…Abstract Number: 2287 • 2019 ACR/ARP Annual Meeting
Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion
Background/Purpose: Immunologic, angiogenic, and anti-angiogenic factors have been associated with spontaneous abortion (SAB), yet early identification of those pregnant women who ultimately undergo SAB remains…Abstract Number: 2288 • 2019 ACR/ARP Annual Meeting
Pregnancy Outcomes in Women Exposed to Golimumab
Background/Purpose: Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic…Abstract Number: 2289 • 2019 ACR/ARP Annual Meeting
Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells
Background/Purpose: Progesterone plays a protective role in preventing inflammation and preterm delivery during pregnancy. However, the mechanism involved is unknown. Microbial product translocation from a…Abstract Number: 2290 • 2019 ACR/ARP Annual Meeting
A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease
Background/Purpose: Undifferentiated connective tissue disease(UCTD) represents a common autoimmune condition in clinical practice, however, therapeutic strategies and follow-up are mostly based on clinician expertise. Little…Abstract Number: 2291 • 2019 ACR/ARP Annual Meeting
Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus
Background/Purpose: Pregnancies in women with systemic lupus erythematosus (SLE) often result in preterm birth. Active disease during pregnancy significantly increases the risks for these poor…Abstract Number: 2292 • 2019 ACR/ARP Annual Meeting
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Background/Purpose: During pregnancy, patients with rheumatoid arthritis (RA) can experience flares that might influence pregnancy outcomes. We aimed at assessing disease course during pregnancy and…Abstract Number: 2293 • 2019 ACR/ARP Annual Meeting
Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age. Cyclophosphamide, an alkylating agent, labelled category D for pregnancy, is used for induction in…
ACR Meeting Abstracts